Tvardi Therapeutics, Inc. TVRD
1.41 USD +0.46 (+48.11%)
At closeNov 9, 2026, 4:55 PM EST
1.49 +0.08 +5.67%
After hours · Nov 9, 4:55 PM ET
0.9577 Day range 1.61
0.773 52-week range 5.69
- YTD
- -67.21%
- 1 year
- -64.93%
- Market cap
- 18.81M
- EPS (ttm)
- -2.84
- YTD return
- -67.21%
- 1-year return
- -64.93%
- Volume
- 1.74M
- Avg volume
- 168.50K
- Open
- 0.96
- Previous close
- 0.952
- Day's range
- 0.9577 – 1.61
- 52-week range
- 0.773 – 5.69
5D +0.1318 (+15.96%)
Financials — quick view
TVRD Revenue — quarterly 0
TVRD Net income — quarterly -6.46M
TVRD EPS — quarterly -0.69
News
12 Health Care Stocks Moving In Monday's After-Market Session 
Chardan Capital Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $8 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
12 Health Care Stocks Moving In Wednesday's After-Market Session - 12 Health Care Stocks Moving In Thursday's Intraday Session
Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular Sciences 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate - Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UC
BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5
Your note
Sign in to keep a note on TVRD — it syncs with the Stock Master app.